Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Clasificación en acciones #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Precio por acción
$150.78
Última sincronización: 2026-09-18
Capitalización bursátil
$187.20B
Cambio (1 día)
-0.08%
Cambio (1 año)
32.15%
País
US
Comercio Gilead Sciences, Inc. (GILD)

Categoría

Margen Operativo de Gilead Sciences, Inc. (GILD)
Margen Operativo al September 2026 TTM: -4.90%
Según los informes financieros más recientes y el precio de las acciones de Gilead Sciences, Inc., el margen operativo actual (TTM) es -4.90%. Al final de 2024, el margen operativo era 5.78%.
Historial de Margen Operativo de Gilead Sciences, Inc. desde 2000 hasta 2026
Margen Operativo al final de cada año
Año Margen Operativo Cambiar
2026 (TTM) -4.90% -114.39%
2025 34.04% 488.93%
2024 5.78% -79.39%
2023 28.05% 4.39%
2022 26.87% -26.02%
2021 36.32% 120.25%
2020 16.49% -13.66%
2019 19.10% -48.46%
2018 37.06% -31.50%
2017 54.10% -6.76%
2016 58.02% -14.68%
2015 68.00% 10.88%
2014 61.33% 51.84%
2013 40.39% -2.27%
2012 41.33% -8.56%
2011 45.20% -9.31%
2010 49.84% -0.99%
2009 50.34% 0.28%
2008 50.20% -1.90%
2007 51.17% -304.11%
2006 -25.07% -145.85%
2005 54.68% 15.46%
2004 47.36% -359.08%
2003 -18.28% -205.36%
2002 17.35% -133.60%
2001 -51.63% 93.01%
2000 -26.75% 0.00%
Margen Operativo de empresas similares o competidoras
Empresa Margen Operativo Diferencia de Margen Operativo País
43.92% -108.96%
US
26.81% -105.47%
US
29.32% -105.98%
US
26.59% -105.43%
CH
16.65% -103.40%
US
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.